Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Declines By 25.4%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 69,800 shares, a drop of 25.4% from the September 30th total of 93,600 shares. Based on an average daily volume of 1,320,000 shares, the short-interest ratio is currently 0.1 days. Currently, 1.6% of the company’s shares are sold short.

Vivos Therapeutics Stock Performance

NASDAQ:VVOS traded down $0.02 during trading hours on Friday, hitting $2.65. The stock had a trading volume of 79,240 shares, compared to its average volume of 506,457. The business’s 50 day moving average is $2.75 and its 200-day moving average is $2.49. The company has a market cap of $8.55 million, a price-to-earnings ratio of -0.24 and a beta of 7.72. Vivos Therapeutics has a one year low of $1.91 and a one year high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.60) EPS for the quarter. The business had revenue of $4.05 million for the quarter. Vivos Therapeutics had a negative return on equity of 652.32% and a negative net margin of 85.90%. On average, sell-side analysts anticipate that Vivos Therapeutics will post -3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets boosted their target price on Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research report on Tuesday, August 20th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.